M-Insightlogo
  • Multiple Myeloma & MRD
    dropmenu
    What is Multiple Myeloma?
    MM is a blood cancer characterized by the clonal expansion of plasma cells in the bone marrow. Myeloma is rare, accounting for 1% of all cancers.
    dropmenu
    MM diagnosis and monitoring
    Multiple myeloma diagnosis and monitoring are based on clinical symptoms and a variety of laboratory tests. M-protein detection and quantification are integral parts of diagnosis and monitoring of MM.
    dropmenu
    What is MRD ?
    MRD stands for Minimal Residual Disease. It refers to the very small number of myeloma cells that are present in the bone marrow after treatment. These remaining cells often cannot be detected through traditional tests of treatment response. However, they have the potential to multiply and cause relapse.
  • M-inSight®
  • Resources
  • About us
    dropmenu
    Corgenix
    CAP/CLIA Clinical Laboratory: Precision disease monitoring tools powered by advanced proteomics and clinical excellence.
    dropmenu
    Meet the M-inSight® Team
    M-inSight® was developed by a team of myeloma experts and scientific innovators committed to improving how patients are monitored—using advanced technology to deliver clearer, less invasive testing.
    dropmenu
    Sebia
    Center of Excellence for Research and Development: Our mission is to create advanced tools that translate complex biological signals from the patient’s body into clear, interpretable data.
  • Contact us
  • How to order?
    • Order M-inSight®
  • Multiple Myeloma & MRD
  • M-inSight®
  • Resources
  • About us
  • Contact us
  • How to order?
  • Order M-inSight®
  • Back
  • What is Multiple Myeloma?
  • MM diagnosis and monitoring
  • What is MRD ?
  • Back
  • Corgenix
  • Meet the M-inSight® Team
  • Sebia

Author: cbernier@sebia.com

November 2024

MRD tracking in blood using a de novo sequencing from SPEP gel of M-protein in Multiple Myeloma Patients – IMS 2024
November 2024

Urine Bence Jones proteins as a novel source for De Novo light chain sequencing – IMS 2024
August 2024

Advances in minimal residual disease monitoring in multiple myeloma – Clinical Laboratory Sciences 2023
August 2024

Single MS assay targeting m-protein, therapeutic antibodies, polyclonal immunoglobulins provides unique insight into therapy response kinetics in patients with MM – EMN 2024
August 2024

Next Generation Monitoring: M-inSight® Clinical Application In Multiple Myeloma – ADLM 2024
August 2024

An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and MRD monitoring in MM patients – CCLM 2024
August 2024

M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator – CCLM 2024
December 2023

Monitoring of Systemic Light-Chain Amyloidosis patients using Mass Spectrometry (M-inSight) in serum – ASH 2023
December 2023

Multiple Myeloma MRD tracking in blood using ultra sensitive Mass Spectrometry (M-inSight) – ASH 2023
October 2023

Personalized mass spectrometry as a tool for minimal residual disease detection in the blood of myeloma patients – IMS 2023
  • Précédent
  • 1
  • 2
  • 3
  • 4
  • Suivant
See what others can't
Order M-inSight®

Multiple Myeloma & MRD

Multiple Myeloma MRD Monitoring Diagnosis and Monitoring

M-inSight®

Discover M-inSight® Ordering information Resources Contact us
© 2026 M-inSight®
Terms of Use
Privacy policy
Privacy Practices
Claims presented in the website are supported by references on the Resources page.